Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:ALT NASDAQ:AVIR NASDAQ:EPIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.08-12.2%$1.28$0.86▼$3.78$269.04M0.353.85 million shs19.09 million shsALTAltimmune$3.61-2.2%$5.14$2.90▼$11.16$299.29M-0.013.61 million shs1.80 million shsAVIRAtea Pharmaceuticals$3.47-4.7%$3.41$2.45▼$4.14$311.51M0.25376,402 shs313,746 shsEPIXESSA Pharma$1.88$1.76$1.40▼$7.88$83.45M1.55476,027 shs153,036 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-12.20%-28.00%-10.00%-36.47%-63.27%ALTAltimmune-2.17%-11.52%-26.33%-37.44%-43.24%AVIRAtea Pharmaceuticals-4.67%-11.03%-4.41%+16.44%-9.16%EPIXESSA Pharma0.00%0.00%+10.59%+8.67%-64.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLOAllogene Therapeutics2.9872 of 5 stars4.52.00.00.00.82.50.6ALTAltimmune2.2452 of 5 stars3.43.00.00.01.31.70.6AVIRAtea Pharmaceuticals1.692 of 5 stars3.30.00.00.00.62.51.3EPIXESSA Pharma1.1884 of 5 stars1.05.00.00.00.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.90Moderate Buy$8.44681.89% UpsideALTAltimmune 2.75Moderate Buy$18.20404.16% UpsideAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0072.91% UpsideEPIXESSA Pharma 2.00Hold$2.006.38% UpsideCurrent Analyst Ratings BreakdownLatest EPIX, AVIR, ALT, and ALLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.006/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/15/2025ALLOAllogene TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.005/14/2025ALLOAllogene TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.005/14/2025ALLOAllogene TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K11,811.42N/AN/A$2.01 per share0.54ALTAltimmune$20K14,640.36N/AN/A$1.74 per share2.07AVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/AEPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)ALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)AVIRAtea Pharmaceuticals-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/7/2025 (Estimated)EPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)Latest EPIX, AVIR, ALT, and ALLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALTAltimmune-$0.3006N/AN/AN/A$0.00 millionN/A8/7/2025Q2 2025AVIRAtea Pharmaceuticals-$0.44N/AN/AN/AN/AN/A8/6/2025N/AALLOAllogene Therapeutics-$0.28N/AN/AN/AN/AN/A8/4/2025Q3 2025EPIXESSA Pharma-$0.2430N/AN/AN/AN/AN/A5/13/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/A5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.719.71ALTAltimmuneN/A15.8515.85AVIRAtea PharmaceuticalsN/A19.9419.94EPIXESSA PharmaN/A67.1567.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%ALTAltimmune78.05%AVIRAtea Pharmaceuticals86.67%EPIXESSA Pharma75.12%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%ALTAltimmune4.10%AVIRAtea Pharmaceuticals18.10%EPIXESSA Pharma15.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310218.73 million189.86 millionOptionableALTAltimmune5081.11 million77.78 millionOptionableAVIRAtea Pharmaceuticals7085.58 million70.09 millionOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableEPIX, AVIR, ALT, and ALLO HeadlinesRecent News About These CompaniesESSA Pharma (EPIX) Expected to Announce Earnings on MondayAugust 2 at 2:37 AM | americanbankingnews.comESSA Pharma Announces Tax Implications of Cash DistributionAugust 1 at 4:19 AM | msn.comESSA Pharma (EPIX) Expected to Announce Quarterly Earnings on MondayJuly 28, 2025 | marketbeat.comESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to ShareholdersJuly 23, 2025 | prnewswire.comESSA Pharma (NASDAQ:EPIX) Trading Up 8.8% - What's Next?July 14, 2025 | marketbeat.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of ESSA Pharma Inc. (NASDAQ: EPIX)July 14, 2025 | globenewswire.comEPIX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of ESSA Pharma Inc. is Fair to ShareholdersJuly 14, 2025 | businesswire.comESSA Pharma to be Acquired by XenoTherapeuticsJuly 14, 2025 | tipranks.comESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash TransactionJuly 14, 2025 | prnewswire.comEPIX | Essa Pharma Inc. Annual Income Statement - MarketWatchJuly 3, 2025 | marketwatch.comESSA Pharma Inc. Explores Strategic Alternatives After Clinical Trial TerminationMay 9, 2025 | tipranks.comESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025May 8, 2025 | prnewswire.comInvestor pressures struggling Essa to liquidate, give cash to shareholdersApril 16, 2025 | fiercebiotech.comFShareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIXMarch 25, 2025 | accessnewswire.comAESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIXMarch 25, 2025 | prnewswire.comEPIX Deadline Today: Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Large Losses to Contact the Firm for Information About Their RightsMarch 25, 2025 | businesswire.comESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIXMarch 25, 2025 | accessnewswire.comAEPIX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EPIXMarch 25, 2025 | accessnewswire.comAInvestors who lost money on ESSA Pharma Inc.(EPIX) should contact Levi & Korsinsky about pending Class Action - EPIXMarch 25, 2025 | accessnewswire.comAESSA Pharma Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – EPIXMarch 24, 2025 | accessnewswire.comAESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff MotionMarch 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRocket Lab: A Parabolic Run Meets a Healthy PullbackBy Ryan Hasson | July 23, 2025View Rocket Lab: A Parabolic Run Meets a Healthy PullbackForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffDo They Know Something? Insiders & Congress Buy UnitedHealthBy Brian O'Connell | July 9, 2025View Do They Know Something? Insiders & Congress Buy UnitedHealthInsiders Spent Millions on These 3 Stocks Over the Past 2 MonthsBy Leo Miller | July 17, 2025View Insiders Spent Millions on These 3 Stocks Over the Past 2 MonthsHealthcare Stocks Hit Valuation Bottom, 3 Names to ReboundBy Gabriel Osorio-Mazilli | July 23, 2025View Healthcare Stocks Hit Valuation Bottom, 3 Names to ReboundEPIX, AVIR, ALT, and ALLO Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.08 -0.15 (-12.20%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.08 -0.01 (-0.46%) As of 08/1/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Altimmune NASDAQ:ALT$3.61 -0.08 (-2.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.64 +0.04 (+0.97%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Atea Pharmaceuticals NASDAQ:AVIR$3.47 -0.17 (-4.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.48 +0.00 (+0.14%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.ESSA Pharma NASDAQ:EPIX$1.88 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.88 0.00 (0.00%) As of 08/1/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.